429 related articles for article (PubMed ID: 34512654)
21. Identification of a Prognosis-Related Risk Signature for Bladder Cancer to Predict Survival and Immune Landscapes.
Wang L; Wang Y; Wang J; Li L; Bi J
J Immunol Res; 2021; 2021():3236384. PubMed ID: 34708131
[TBL] [Abstract][Full Text] [Related]
22. FGL2 as a predictive biomarker for prognosis and immunotherapy in bladder cancer.
Huang Z; Wang Z; Xu C; Yan Y; Cao X; Zhang F; Shen B
Int J Med Sci; 2024; 21(8):1447-1460. PubMed ID: 38903931
[No Abstract] [Full Text] [Related]
23. Therapeutic Benefits and Prognostic Value of a Model Based on 7 Immune-associated Genes in Bladder Cancer.
Cao M; Cao Y; Xue S; Zhang Q; Zhang H; Xue W
Altern Ther Health Med; 2024 Apr; 30(4):130-138. PubMed ID: 38518167
[TBL] [Abstract][Full Text] [Related]
24. A novel cuproptosis-related lncRNA signature predicts the prognosis and immune landscape in bladder cancer.
Bai Y; Zhang Q; Liu F; Quan J
Front Immunol; 2022; 13():1027449. PubMed ID: 36451815
[TBL] [Abstract][Full Text] [Related]
25. Clinical Significance and Immunologic Landscape of a Five-IL(R)-Based Signature in Lung Adenocarcinoma.
Fan T; Pan S; Yang S; Hao B; Zhang L; Li D; Geng Q
Front Immunol; 2021; 12():693062. PubMed ID: 34497605
[TBL] [Abstract][Full Text] [Related]
26. Identification of five long noncoding RNAs signature and risk score for prognosis of bladder urothelial carcinoma.
Zhang C; Li Z; Hu J; Qi F; Li X; Luo J
J Cell Biochem; 2020 Jan; 121(1):856-866. PubMed ID: 31373406
[TBL] [Abstract][Full Text] [Related]
27. Multi-Omics analysis identifies a lncRNA-related prognostic signature to predict bladder cancer recurrence.
Xu Z; Chen H; Sun J; Mao W; Chen S; Chen M
Bioengineered; 2021 Dec; 12(2):11108-11125. PubMed ID: 34738881
[TBL] [Abstract][Full Text] [Related]
28. Immune-related signature predicts the prognosis and immunotherapy benefit in bladder cancer.
Wang Y; Chen L; Yu M; Fang Y; Qian K; Wang G; Ju L; Xiao Y; Wang X
Cancer Med; 2020 Oct; 9(20):7729-7741. PubMed ID: 32841548
[TBL] [Abstract][Full Text] [Related]
29. A novel survival model based on a Ferroptosis-related gene signature for predicting overall survival in bladder cancer.
Liang Y; Ye F; Xu C; Zou L; Hu Y; Hu J; Jiang H
BMC Cancer; 2021 Aug; 21(1):943. PubMed ID: 34418989
[TBL] [Abstract][Full Text] [Related]
30. Siglec15 shapes a non-inflamed tumor microenvironment and predicts the molecular subtype in bladder cancer.
Hu J; Yu A; Othmane B; Qiu D; Li H; Li C; Liu P; Ren W; Chen M; Gong G; Guo X; Zhang H; Chen J; Zu X
Theranostics; 2021; 11(7):3089-3108. PubMed ID: 33537076
[No Abstract] [Full Text] [Related]
31. A novel signature constructed by mitochondrial function and cell death-related gene for the prediction of prognosis in bladder cancer.
Yan Z; Liu Y; Wang M; Wang L; Chen Z; Liu X
Sci Rep; 2024 Jun; 14(1):14667. PubMed ID: 38918587
[TBL] [Abstract][Full Text] [Related]
32. Tumor stemness score to estimate epithelial-to-mesenchymal transition (EMT) and cancer stem cells (CSCs) characterization and to predict the prognosis and immunotherapy response in bladder urothelial carcinoma.
Zhang Y; Zhang X; Huang X; Tang X; Zhang M; Li Z; Hu X; Zhang M; Wang X; Yan Y
Stem Cell Res Ther; 2023 Feb; 14(1):15. PubMed ID: 36721217
[TBL] [Abstract][Full Text] [Related]
33. Identification and validation of a signature based on myofibroblastic cancer-associated fibroblast marker genes for predicting prognosis, immune infiltration, and therapeutic response in bladder cancer.
Qin R; Ma X; Pu S; Shen C; Hu D; Liu C; Wang K; Wang Y
Investig Clin Urol; 2024 May; 65(3):263-278. PubMed ID: 38714517
[TBL] [Abstract][Full Text] [Related]
34. An Epithelial-Mesenchymal Transition (EMT) Preoperative Nomogram for Prediction of Lymph Node Metastasis in Bladder Cancer (BLCA).
Cao R; Ma B; Wang G; Xiong Y; Tian Y; Yuan L
Dis Markers; 2020; 2020():8833972. PubMed ID: 33204364
[TBL] [Abstract][Full Text] [Related]
35. Four types of adenine-related RNA modification writers -mediated molecular subtypes contribute to predicting clinical outcomes and treatment options in bladder cancer.
Zhang Y; Chen Y; Wen W
Front Immunol; 2023; 14():1152806. PubMed ID: 37638051
[TBL] [Abstract][Full Text] [Related]
36. Identification of autophagy-related genes signature predicts chemotherapeutic and immunotherapeutic efficiency in bladder cancer (BLCA).
Cao R; Ma B; Wang G; Xiong Y; Tian Y; Yuan L
J Cell Mol Med; 2021 Jun; 25(12):5417-5433. PubMed ID: 33960661
[TBL] [Abstract][Full Text] [Related]
37. Basement membrane-related MMP14 predicts poor prognosis and response to immunotherapy in bladder cancer.
Zhang X; Hong B; Li H; Zhao J; Li M; Wei D; Wang Y; Zhang N
BMC Cancer; 2024 Jun; 24(1):746. PubMed ID: 38898429
[TBL] [Abstract][Full Text] [Related]
38. Tumor Expression Profile Analysis Developed and Validated a Prognostic Model Based on Immune-Related Genes in Bladder Cancer.
Dong B; Liang J; Li D; Song W; Zhao S; Ma Y; Song J; Zhu M; Yang T
Front Genet; 2021; 12():696912. PubMed ID: 34512722
[No Abstract] [Full Text] [Related]
39. Identification of an immune-related long non-coding RNA signature and nomogram as prognostic target for muscle-invasive bladder cancer.
Song Y; Jin D; Chen J; Luo Z; Chen G; Yang Y; Liu X
Aging (Albany NY); 2020 Jun; 12(12):12051-12073. PubMed ID: 32579540
[TBL] [Abstract][Full Text] [Related]
40. Identification and Validation of a Tumor Microenvironment-Related Gene Signature for Prognostic Prediction in Advanced-Stage Non-Small-Cell Lung Cancer.
Zhang X; Shi X; Zhao H; Jia X; Yang Y
Biomed Res Int; 2021; 2021():8864436. PubMed ID: 33860055
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
